OPKO Health To Present New Clinical Data On Rayaldee At Kidney Week 2023
Portfolio Pulse from Benzinga Newsdesk
OPKO Health, Inc. (NASDAQ:OPK) will present new clinical data on RAYALDEE, an extended-release calcifediol, at the American Society of Nephrology Kidney Week in November 2023. The data will demonstrate that RAYALDEE effectively raises serum levels of 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D in non-dialysis patients with secondary hyperparathyroidism, making it an alternative to vitamin D hormone therapies. The data also support early initiation of treatment with RAYALDEE to delay disease progression.
October 25, 2023 | 9:19 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
OPKO Health's new clinical data on RAYALDEE could potentially boost the company's reputation and market share in the healthcare sector. The data supports the effectiveness of RAYALDEE in treating secondary hyperparathyroidism and delaying disease progression.
The new clinical data on RAYALDEE, if positive, could potentially increase the demand for the product, leading to increased revenues for OPKO Health. This could have a positive impact on the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100